✦ LIBER ✦

Comparison of fixed dose (6 mg) pegfilgrastim and daily filgrastim to accelerate hemopoietic recovery after autologous stem cell transplantation (ASCT)

✍ Scribed by G. Marcacci; M.C. Petti; F. Ferrara; N. Scarpato; S. Storti; G. D’Arena; F. Palombi; S. Palmieri; C. Andretta; A. Pinto

Book ID: 116278726
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 64 KB
Volume: 12
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2005.11.288

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pegfilgrastim versus filgrastim to accel

Pegfilgrastim versus filgrastim to accelerate hematopoietic recovery after high-dose melphalan and autologous hematopoietic stem cell transplantation (ASCT) for multiple myeloma

✍ R.L. Olin; S.M. Luger; D.L. Porter; S.J. Schuster; D. Tsai; S. Nasta; A. Perl; A 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Comparison of fixed dose pegfilgrastim a

Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis

✍ Felicetto Ferrara; Tiziana Izzo; Clelia Criscuolo; Cira Riccardi; Assunta Viola; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

## Abstract Different authors have explored the feasibility of autografting patients with multiple myeloma (MM) on an outpatient basis. Peg‐filgrastim (PEG), a long‐acting recombinant G‐CSF, has similar efficacy when compared to conventional G‐CSF for chemotherapy‐induced neutropenia, but little is